Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study

G.A. KellerDepartment of Pharmacology, School of Medicine, Universidad de Buenos AiresArgentina;Department of Physiological, Biochemical and Pharmacological Sciences, School of Medicine, Universidad Favaloro Buenos Aires, Argentina

P. CzerniukCentro de Medicina Integral SRL Buenos Aires, Argentina

R. BertuolaCentro de Medicina Integral SRL Buenos Aires, Argentina

F. de MenaIACA Laboratorios, Buenos Aires, Argentina

M.V. SimoniIACA Laboratorios, Buenos Aires, Argentina

A.R. AssefiMedical Department – Laboratorios Phoenix S.A.I.C. y F. Buenos Aires, Argentina

G. Di GirolamoDepartment of Pharmacology, School of Medicine, Universidad de Buenos AiresArgentina;Department of Physiological, Biochemical and Pharmacological Sciences, School of Medicine, Universidad Favaloro Buenos Aires, ArgentinaCorrespondence[email protected]

show all

Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date